RedHill’s COVID-19 programme is progressing well with two clinical trials ongoing, a Phase II study (n=40) in the US and an international Phase II/III study (n=270). If results are promising, RedHill plans to apply for emergency use authorisation as soon as possible. The commercial highlight this year was the acquisition of Movantik (for opioid-induced constipation) from AstraZeneca on 1 April 2020. Q220 was the first full quarter of RedHill promoting Movantik with booked sales of $20.9
12 Oct 2020
RedHill Biopharma - Rapid COVID-19 Ph II/III programme progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
RedHill Biopharma - Rapid COVID-19 Ph II/III programme progress
- Published:
12 Oct 2020 -
Author:
Dr Jonas Peciulis -
Pages:
2
RedHill’s COVID-19 programme is progressing well with two clinical trials ongoing, a Phase II study (n=40) in the US and an international Phase II/III study (n=270). If results are promising, RedHill plans to apply for emergency use authorisation as soon as possible. The commercial highlight this year was the acquisition of Movantik (for opioid-induced constipation) from AstraZeneca on 1 April 2020. Q220 was the first full quarter of RedHill promoting Movantik with booked sales of $20.9